Predicting outcomes of pre-surgery treatment for non-small cell lung cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study will enroll patients with pathologically confirmed NSCLC who receive neoadjuvant chemo‑immunotherapy followed by surgical resection at two tertiary hospitals in China. Investigators will collect clinical information, imaging, pathological response data, and available molecular markers to build a multimodal predictive model. Machine learning methods will be used to train the model on part of the cohort and validate performance on held‑out and external center cases when available. The aim is to produce a tool that forecasts pathological response to neoadjuvant therapy and can inform preoperative decision making.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. pathologically diagnosed non-small cell lung cancer
2. The treatment plan is：receiving neoadjuvant chemo-immunotherapy during the study period, followed by surgical resection

Exclusion Criteria:

1. recurrent or metastatic lung cancer;
2. patients with other primary tumors

Where it's running

• Tongji hospital
  Wuhan, Hubei, China Recruiting
• Sir Run Run Shaw Hospital
  Hangzhou, Zhejiang, China Recruiting

Study contacts

• Study coordinator: Minghao Hu
• Email: huminghao2010@126.com
• Phone: 8613396366466

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Firmonertinib given before surgery for EGFR-mutated NSCLC

  This study tests whether taking firmonertinib before and around surgery helps patients with resectable EGFR-mutated NSCLC see more tumor shrinkage before the operation.

  Recruiting Phase 2 Peking University Cancer Hospital & Institute · Beijing · NCT07622706

• MRD-guided postoperative monitoring and adaptive treatment for resectable NSCLC

  This study tests a personalized follow-up and treatment plan using ctDNA MRD testing and pathology to guide adjuvant therapy after surgery for stage IB-IIIA NSCLC treated with neoadjuvant immunotherapy.

  Recruiting Peking University People's Hospital · Beijing, Beijing Municipality · NCT07894458

• Targeted alpha therapy for B7-H3 expressing solid tumors using AKY-2519

  This phase 1b trial tests a radiolabeled drug (AKY-2519) to see if it's safe and tolerable in adults with B7-H3 positive advanced solid tumors, including NSCLC and SCLC, with imaging to help guide use.

  Recruiting at 2 sites Phase 1 Aktis Oncology, Inc. · Miami, Florida and 1 other locations · NCT07887971

• SumMET: Targeted radioligand therapy for c-MET–positive solid tumors

  This first‑in‑human study tests the safety and potential effectiveness of a radioligand therapy called [225Ac]Ac-FL-261 in adults with advanced or metastatic solid tumors that overexpress c-MET.

  Recruiting at 2 sites Phase 1/2 Full-Life Technologies UK Limited · Minneapolis, Minnesota and 1 other locations · NCT07873450

• SI-B036 safety test in advanced and metastatic solid tumors

  This early-phase study checks whether SI-B036 is safe and tolerable in adults with advanced or metastatic solid cancers who have had prior therapy.

  Recruiting at 4 sites Phase 1 SystImmune Inc. · New Haven, Connecticut and 6 other locations · NCT07857616

• Perioperative therapy with Retlirafusp alfa, Famitinib, and HAIC-GEMOX for locally advanced intrahepatic cholangiocarcinoma

  This trial tests whether a perioperative treatment combo (Retlirafusp alfa, famitinib, and HAIC-GEMOX) can help shrink or control locally advanced intrahepatic cholangiocarcinoma before surgery and support additional therapy afterward in adults.

  Recruiting Phase 2 The First Affiliated Hospital with Nanjing Medical University · Nanjing, Jiangsu · NCT07847710

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.